Neoplasms, Plasma Cell: all 2,314 studies
Page 2 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Two Schemes Response in Multiple MyelomaRecruitingNCT06284395
- UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT06279026Not applicable
- A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL StudyRecruitingNCT06271252Phase 1
- Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMMRecruitingNCT06255847Phase 2
- Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral CollapseRecruitingNCT06255639
- European Rare Blood Disorders Platform (ENROL)RecruitingNCT06250595
- Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple MyelomaRecruitingNCT06246162Phase 1/2
- Bortezomib-bendamustine-melphalan vs Melphalan for Multiple MyelomaRecruitingNCT06245629
- Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT06242249Phase 1/2
- A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.RecruitingNCT06232096Phase 1/2
- The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical TrialRecruitingNCT06228794
- A Trial of Selinexor, Ruxolitinib and MethylprednisoloneRecruitingNCT06225310Phase 1
- A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06223646Phase 1/2
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple MyelomaRecruitingNCT06209606Early Phase 1
- A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMMRecruitingNCT06203145Not applicable
- Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)RecruitingNCT06196255Phase 1/2
- Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSRecruitingNCT06189833Phase 2
- FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)RecruitingNCT06187441Phase 3
- All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple MyelomaRecruitingNCT06158412Phase 2
- DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple MyelomaRecruitingNCT06158269Phase 2
- Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)RecruitingNCT06154317
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingNCT06152575Phase 3
- Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple MyelomaRecruitingNCT06149910
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingNCT06140966Phase 2
- Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple MyelomaRecruitingNCT06132711Phase 1/2
- A Study of CM313 in Subjects With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT06126237Phase 1/2
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersRecruitingNCT06119685Phase 1/2
- Lapelga vs GastrofilNot yet recruitingNCT06116734Phase 3
- A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple MyelomaRecruitingNCT06115135Phase 2
- A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial TreatmentRecruitingNCT06109233
- A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaRecruitingNCT06084962Phase 1
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Phase 1/2
- Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R MyelomaRecruitingNCT06066359Phase 1/2
- Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple MyelomaRecruitingNCT06060080Not applicable
- To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLRecruitingNCT06045091Early Phase 1
- Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple MyelomaRecruitingNCT06039735
- Real-World Mapping Antithrombotic Regimens in MM Patients on TreatmentRecruitingNCT06028087
- Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)Not yet recruitingNCT06007989
- A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of TherapyRecruitingNCT05998928Phase 2
- Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple MyelomaRecruitingNCT05996367Not applicable
- Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab TestsNot yet recruitingNCT05995808Not applicable
- Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic TransplantNot yet recruitingNCT05982275Phase 1/2
- Helical Tomotherapy in Multiple MyelomaRecruitingNCT05970198Not applicable
- Myeloma Novel Drug Discovery Ver 1.2RecruitingNCT05968417
- The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE StudyRecruitingNCT05965115
- Telemonitoring Among Patients With Multiple MyelomaRecruitingNCT05964270Not applicable
- PRO and Wearable Data Insights From Individuals With R/R Multiple MyelomaRecruitingNCT05956457Not applicable
- Bioequivalence Studies of Dasatinib 100 MgNot yet recruitingNCT05944783Phase 4
- A Study of QLS32015 in Patients With Recurrent or Refractory Multiple MyelomaRecruitingNCT05920876Phase 1
- Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMMNot yet recruitingNCT05909826Phase 2
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesRecruitingNCT05908409Phase 1/2
- Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05893693Not applicable
- Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple MyelomaRecruitingNCT05888636
- GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic MalignanciesRecruitingNCT05880043Phase 1/2
- Examination of Trends in Multiple Myeloma Trial Patient ExperiencesNot yet recruitingNCT05860179
- Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma TreatmentRecruitingNCT05858203
- Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT05857982Phase 1/2
- Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma PatientsRecruitingNCT05855122Phase 4
- VitD3 Supplementation in Patients With Multiple MyelomaRecruitingNCT05846880Early Phase 1
- Study of FasT CAR-T GC012F Injection NDMM PatientsRecruitingNCT05840107Early Phase 1
- CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05822037Not applicable
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05759793Phase 1
- Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMRecruitingNCT05749133Phase 1/2
- Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareRecruitingNCT05745285Not applicable
- Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMRecruitingNCT05739188Phase 1/2
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT05719701Phase 1/2
- A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT05698303Phase 1
- Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS AnalysisRecruitingNCT05686447
- Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma PatientsRecruitingNCT05665140Phase 2/3
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 1
- A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsRecruitingNCT05646758Phase 1
- Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma PatientsRecruitingNCT05636787Phase 2
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple MyelomaRecruitingNCT05597345Phase 2
- Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MMRecruitingNCT05594797Phase 2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNot yet recruitingNCT05581875Phase 1/2
- ctDNA Methylation Sequencing for MyelomaRecruitingNCT05578625
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingNCT05573802Phase 1/2
- Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT05561049
- Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First RelapseNot yet recruitingNCT05559788
- LMY-920 for Treatment of Relapsed or Refractory MyelomaRecruitingNCT05546723Phase 1
- A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous TransplantationNot yet recruitingNCT05545202Phase 4
- Telo Genomics Technology to Detect & Profile Multiple Myeloma MRDRecruitingNCT05530096
- A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT05521802Phase 1/2
- Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)RecruitingNCT05509530Phase 2
- Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS InvolvementRecruitingNCT05478993Phase 2
- Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.RecruitingNCT05477797Not applicable
- Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney InjuryNot yet recruitingNCT05429515Phase 4
- Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT05422027Phase 1/2
- Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple MyelomaRecruitingNCT05378971Not applicable
- Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple MyelomaNot yet recruitingNCT05353907
- Efficacy and Safety Evaluation of PD1-BCMA-CARTNot yet recruitingNCT05308875Not applicable
- A Study of CM336 in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT05299424Phase 1/2
- A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNot yet recruitingNCT05298683Phase 2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleRecruitingNCT05280275Phase 1/2
- A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple MyelomaRecruitingNCT05271682Phase 1
- Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaRecruitingNCT05248633Phase 2
- Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple MyelomaRecruitingNCT05243212Phase 1/2
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05219721Phase 1
- Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.RecruitingNCT05203003
- A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)Not yet recruitingNCT05181501Phase 1